Sign In
Buy OPNT
$20.65
+0 (+0%)
At Close: May 26, 2023
What's The Opiant CVR Worth?
03:50am, Saturday, 11'th Feb 2023
Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug helps with opioid reversal after an overdose and has
Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In
02:26pm, Friday, 13'th Jan 2023
I love to get a CVR during a takeover process. This happens a lot when pharma or biotech companies with important unapproved assets get bought.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
12:07pm, Tuesday, 06'th Dec 2022
NEW YORK , Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches
Why Is Opiant Pharma (OPNT) Stock Up 116% Today?
10:58am, Monday, 14'th Nov 2022
Opiant Pharmaceuticals (NASDAQ: OPNT ) stock is rocketing higher on Monday following news that Indivior is acquiring the Narcan maker! Indivior is offering to acquire shares of OPNT stock for $28 each
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
04:05pm, Thursday, 27'th Oct 2022
SANTA MONICA, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat a
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2022 Results - Earnings Call Transcript
09:10am, Friday, 12'th Aug 2022
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Ben Atkins - VP Communications and Investor Relations Roger Crystal - Presi
Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
04:05pm, Monday, 01'st Aug 2022
SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat a
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q1 2022 Results - Earnings Call Transcript
06:34pm, Saturday, 14'th May 2022
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT ) Q1 2022 Results Conference Call May 10, 2022 4:30 PM ET Company Participants Ben Atkins - Vice President, Communications and Investor Relations Dr. Roger Cr
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
08:00am, Tuesday, 03'rd May 2022
SANTA MONICA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug
Why Opiant Pharmaceuticals Shares Are Soaring Today
09:06am, Thursday, 28'th Apr 2022
Opiant Pharmaceuticals Inc (NASDAQ: OPNT) announced topline results from a pharmacodynamic (PD) study for OPNT003, nasal nalmefene for opioid overdose. This crossover study conducted in healthy vol
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript
11:00pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M
08:09pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01.Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M.
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
08:05pm, Tuesday, 15'th Mar 2022 GlobeNewswire
SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include:
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript
07:00pm, Tuesday, 15'th Mar 2022
Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q4 2021 Results - Earnings Call Transcript
Opiant Pharmaceuticals Q4 Earnings Preview
09:35pm, Monday, 14'th Mar 2022 Seeking Alpha
Opiant Pharmaceuticals (NASDAQ:OPNT) is scheduled to announce Q4 earnings results on Tuesday, Mar. 15, after market close.Consensus EPS estimate is $0.10 and consensus revenue estimate…
